ACTICOR BIOTECH SUMMARY
Acticor Biotech is a spin-off company from Inserm (French National Institute of Health and Medical Research) founded in November 2013 and located in the Inserm U1148 buildings inside the Bichat Hospital in Paris.
Acticor Biotech develops a drug candidate based on academic research on therapeutic monoclonal antibodies conducted by its founders. This biodrug will aim at reducing death, disabilities and recurrence of ischemic stroke.
Excellent efficacy and innocuity (no bleedings) have been demonstrated on the most pertinent animal models, resulting in a very favorable risk/benefit ratio.
Acticor Biotech is presently closing the drug discovery phase of the development by optimizing the compound for industrial production. The preclinical phase will start in early Q3 2014 as soon as the seed funding is secured.
Partners and awards
This project was selected for incubation by Agoranov in Paris and won twice the Concours d’Aide à la Création d’Entreprises de Technologies Innovantes (CETI), a national competition selecting and supporting the creation of the most promising innovative startups, successively in “emergence” and “creation & development” categories. This academic research phase of the project also received a strong support from top French institutions like the ANR (The French National Research Agency), the Fondation de France and the prize for innovation from the Société Générale Asset Management (SGAM).
